SNDX 250117 15.00C (SNDX250117C15000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

SNDX250117C15000

Watchlist

0.25
-0.09-26.47%

15min DelayClose Jan 6 16:00 ET

0.50High0.25Low

Intraday

5D
Daily

News

Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
PR Newswire07:00 ET
Jefferies Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $43
Moomoo News23:31 ET · Ratings
BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $25
Moomoo NewsJan 6 06:31 ET · Ratings
Express News | Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ReutersJan 3 16:05 ET
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireJan 3 16:05 ET
Syndax Pharmaceuticals Restructures Leadership Team
TipRanksDec 20, 2024 17:31 ET

Comments

Trytosaveabit

Dec 9, 2024 06:45

Update

$Syndax Pharmaceuticals (SNDX.US)$ Reuters· 11 mins ago
Syndax Pharmaceuticals: Subgroup Analyses From Ph 2 Protocol-Defined R/R Mnpm1 Aml Efficacy Population Show Responses Across All Major Subgroups

Jaguar8

Nov 17, 2024 13:32

J.P. Morgan analyst has maintained their bullish stance on stock, giving a Buy rating on November 13. Goldman Sachs give it price target $31.

$Syndax Pharmaceuticals (SNDX.US)$

Jaguar8

Nov 16, 2024 16:41

My watchlist Monday. Why? FDA approval- first of its kind for acute adult and pediatric leukemia

$Syndax Pharmaceuticals (SNDX.US)$

Trytosaveabit

Nov 15, 2024 18:07

Repost of FDA approval! Longer PR because to me this seems like a pretty big deal? More so than most approvals! JMO

$Syndax Pharmaceuticals (SNDX.US)$ But im sure/hoping Dr @Jaguar8 will either confirm or dispute! To me seems pretty AWESOME! ((((((. Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
1 HOUR AGO, 5:29 PM EST
VIA PR NEWSWIRE
– Approva...

Jaguar8

Nov 15, 2024 16:32

NEWS RECAP

$Syndax Pharmaceuticals (SNDX.US)$
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation